UKCTOCS 中高级别浆液性输卵管卵巢癌女性的肿瘤分期、治疗与生存:一项随机对照试验的探索性分析
UKCTOCS 是一项 13 中心随机对照试验,纳入 50–74 岁绝经后女性,按 2:1:1 随机分配至不筛查、多模式筛查或超声筛查。本探索性分析比较多模式筛查组与不筛查组中高级别浆液性癌患者的分期、治疗和生存,发现多模式筛查组晚期诊断比例更低(75% vs 86%)、更多患者接受原发手术和达到零残留病灶,18 年生存绝对差异为 6.9%(95%CI 0.4–13.0;p=0.042)。
要点
- 多模式筛查组晚期(III/IV 期)高级别浆液性癌比例低于不筛查组(195/259 [75%] vs 446/520 [86%];p=0.0003)。
- 多模式筛查组更多患者接受原发手术(158/259 [61%] vs 219/520 [42%];p<0.0001)和达到零残留病灶(119/259 [46%] vs 157/520 [30%];p<0.0001)。
- 18 年时多模式筛查组高级别浆液性癌生存率绝对差异为 6.9%(95%CI 0.4–13.0;p=0.042),21% vs 14%。
核心结论
- 据作者所知,这是首个证据表明筛查可比不筛查更早发现高级别浆液性癌并改善短期治疗结局。
- 高级别浆液性癌女性的潜在生存获益较小,最可能归因于早期检测和治疗改善的幅度有限以及肿瘤生物学。
- 试验的累积结果提示,目前不应将替代终点用于卵巢癌筛查试验的疾病特异性死亡率评价。
研究设计与样本
- UKCTOCS 是一项 13 中心随机对照试验,纳入 50–74 岁、卵巢完整的普通人群绝经后女性,于 2001 年 4 月 17 日至 2005 年 9 月 29 日招募。
- 试验管理系统按 2:1:1 比例以 32 为区组、使用计算机生成的随机数,将符合条件参与者随机分配至不筛查或每年筛查(多模式筛查或超声筛查),直至 2011 年 12 月 31 日。
- 随访通过国家登记处进行至 2020 年 6 月 30 日;一个对随机分组设盲的结局审查委员会裁定卵巢癌诊断、组织学类型、分期和死因。
- 本分析为意向筛查比较,纳入截至 2014 年 12 月 31 日确诊高级别浆液性癌的女性,比较多模式筛查组与不筛查组,分期和治疗终点使用描述性统计,生存采用 Versatile 检验从随机化开始计算。
- 共招募 202 562 名符合条件女性:多模式筛查组 50 625 名,超声筛查组 50 623 名,不筛查组 101 314 名。
主要发现
- 多模式筛查组 50 625 名参与者中 259 名(0.5%)诊断为高级别浆液性癌,不筛查组 101 314 名中 520 名(0.5%)诊断为高级别浆液性癌。
- 与不筛查组相比,多模式筛查组晚期诊断更少(195/259 [75%] vs 446/520 [86%];p=0.0003)。
- 多模式筛查组更多患者接受原发手术(158/259 [61%] vs 219/520 [42%];p<0.0001),更多患者在减瘤术后达到零残留病灶(119/259 [46%] vs 157/520 [30%];p<0.0001),更多患者接受包括手术和化疗的治疗(192/259 [74%] vs 331/520 [64%];p=0.0032)。
- 一线联合化疗率无差异(142/259 [55%] vs 293/520 [56%];p=0.69)。
- 多模式筛查组和不筛查组 779 名高级别浆液性癌女性从随机化开始的中位随访为 9.51 年(IQR 6.04–13.00);截至 2020 年 6 月 30 日,18 年时多模式筛查组从随机化开始的生存长于不筛查组,绝对生存差异为 6.9%(95%CI 0.4–13.0;p=0.042),21%(95%CI 15.6–26.2)vs 14%(95%CI 10.5–17.4)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In UKCTOCS, there was a decrease in the diagnosis of advanced stage tubo-ovarian cancer but no reduction in deaths in the multimodal screening group compared with the no screening group. Therefore, we did exploratory analyses of patients with high-grade serous ovarian cancer to understand the reason for the discrepancy. METHODS: UKCTOCS was a 13-centre randomised controlled trial of screening postmenopausal women from the general population, aged 50-74 years, with intact ovaries. The trial management system randomly allocated (2:1:1) eligible participants (recruited from April 17, 2001, to Sept 29, 2005) in blocks of 32 using computer generated random numbers to no screening or annual screening (multimodal screening or ultrasound screening) until Dec 31, 2011. Follow-up was through national registries until June 30, 2020. An outcome review committee, masked to randomisation group, adjudicated on ovarian cancer diagnosis, histotype, stage, and cause of death. In this study, analyses were intention-to-screen comparisons of women with high-grade serous cancer at censorship (Dec 31, 2014) in multimodal screening versus no screening, using descriptive statistics for stage and treatment endpoints, and the Versatile test for survival from randomisation. This trial is registered with the ISRCTN Registry, 22488978, and ClinicalTrials.gov, NCT00058032. FINDINGS: 202 562 eligible women were recruited (50 625 multimodal screening; 50 623 ultrasound screening; 101 314 no screening). 259 (0·5%) of 50 625 participants in the multimodal screening group and 520 (0·5%) of 101 314 in the no screening group were diagnosed with high-grade serous cancer. In the multimodal screening group compared with the no screening group, fewer were diagnosed with advanced stage disease (195 [75%] of 259 vs 446 [86%] of 520; p=0·0003), more had primary surgery (158 [61%] vs 219 [42%]; p<0·0001), more had zero residual disease following debulking surgery (119 [46%] vs 157 [30%]; p<0·0001), and more received treatment including both surgery and chemotherapy (192 [74%] vs 331 [64%]; p=0·0032). There was no difference in the first-line combination chemotherapy rate (142 [55%] vs 293 [56%]; p=0·69). Median follow-up from randomisation of 779 women with high-grade serous cancer in the multimodal and no screening groups was 9·51 years (IQR 6·04-13·00). At censorship (June 30, 2020), survival from randomisation was longer in women with high-grade serous cancer in the multimodal screening group than in the no screening group with absolute difference in survival of 6·9% (95% CI 0·4-13·0; p=0·042) at 18 years (21% [95% CI 15·6-26·2] vs 14% [95% CI 10·5-17·4]). INTERPRETATION: To our knowledge, this is the first evidence that screening can detect high-grade serous cancer earlier and lead to improved short-term treatment outcomes compared with no screening. The potential survival benefit for women with high-grade serous cancer was small, most likely due to only modest gains in early detection and treatment improvement, and tumour biology. The cumulative results of the trial suggest that surrogate endpoints for disease-specific mortality should not currently be used in screening trials for ovarian cancer. FUNDING: National Institute for Health Research, Medical Research Council, Cancer Research UK, The Eve Appeal.
引用
- Menon U, Gentry-Maharaj A, Burnell M, et al. Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial. Lancet Oncol. 2023. PMID: 37657461. doi:10.1016/S1470-2045(23)00335-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。